North Hollywood, CA, March 20, 2015—The International Myeloma Foundation (IMF) — improving the quality of life of myeloma patients while working toward prevention and a cure — will present the 13th annual Robert A. Kyle Lifetime Achievement Award to Prof. Dr. Pieter Sonneveld during a ceremony in Vienna, Austria on June 9, 2015.
Since 2003, the IMF each year has honored an outstanding physician with the award, which is named for its first recipient, Dr. Robert Kyle. The 13th Kyle Lifetime Achievement Award ceremony will be held during the IMF’s annual International Myeloma Working Group (IMWG) Summit in Vienna.
“We applaud Dr. Sonneveld’s accomplishments and decades-long contributions to improving the lives of myeloma patients,” said IMF President Susie Novis. Kyle Award honorees are individuals whose work in the field of myeloma has resulted in significant advances in research, treatment and care of myeloma patients.
“Dr. Sonneveld’s work perfectly reflects the words of Dr. William Mayo, founder of Mayo Clinic, who challenged the nature of patient care nearly a century ago when he said ‘The needs of the patient are the only needs to be considered,’ ” said IMF Chairman Dr. Brian Durie.
“I am very privileged to work with many gifted and dedicated people from all over the world to find a cure for multiple myeloma and to improve the lives of our patients,” Prof. Dr. Sonneveld said. “The international myeloma research community is special because of the many interactions and cooperative research with colleagues and patients. I feel honored to receive the 2015 Robert A. Kyle Lifetime Achievement Award and I share it with the people who participated in our trials and research during many years.”
Prof. Dr. Pieter Sonneveld, MD, Ph.D., is the Head of the Department of Hematology and Professor of Hematology at the Erasmus University in Rotterdam, The Netherlands. He received his medical degree from the Erasmus University in 1977. In 1980, he completed his Ph.D. thesis on the pharmacology of Adriamycin in acute leukemia at the University of Leiden. He subsequently received a Fogarty Fellowship and worked for two years at the National Cancer Institute (NCI) in the U.S.
Prof. Dr. Sonneveld is Chairman of the Dutch HOVON Myeloma Cooperative Group and he coordinates clinical trials in lymphoma, leukemia and multiple myeloma in The Netherlands. He is on the executive board of the European Hematology Association (EHA). He serves on the Scientific Advisory Boards of the IMF, the Myeloma UK Foundation, is a member of the Editorial Boards of more than eight major hematology publications, and is Associate Editor of Haematologica. He is Chairman of the European Myeloma Network.